Safety, Tolerability, Preliminary Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of MYK-461 in Healthy Volunteers

Trial Profile

Safety, Tolerability, Preliminary Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of MYK-461 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Mavacamten (Primary)
  • Indications Hypertrophic cardiomyopathy
  • Focus Adverse reactions; First in man
  • Sponsors MyoKardia
  • Most Recent Events

    • 16 Nov 2016 Results from NCT02329184 and NCT02356289 studies, presented at the 89th Annual Scientific Sessions of the American Heart Association.
    • 11 Jul 2016 Results from this trial have been submitted for presentation at The American Heart Association's Scientific Sessions 2016, according to a MyoKardia media release.
    • 11 Jul 2016 Results published in a MyoKardia media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top